Description: The applicant describes a five-year program leading to independent translational research related to gastrointestinal cancer. The goals of this career development program are: 1) to further the ongoing research in biomarker discovery for colorectal cancer, 2) to gain new knowledge and experience with proteomic technology, and 3) to become an independent researcher focused on the development of novel diagnostic and therapeutic modalities for gastrointestinal cancer. Laboratory skills in molecular biology, mouse models, genomics, and proteomics will be fostered in the laboratory of one of the co-mentors, Dr. Raju Kucherlapati. He is an accomplished scientist with vast experience in mouse models of cancer, genomics, and proteomics. The other co-mentor, Dr. Daniel Podolsky, will serve as a clinical and scientific advisor to the project and foster the professional development of the investigator. Colorectal cancer is the third leading cause of cancer-related mortality in the United States. As stated in The Nation's Investment in Cancer Research FY 2006, we will be able """"""""to eliminate the suffering and death due to cancer"""""""" when we are able to """"""""detect many cancers early enough to make successful treatment possible."""""""" Early diagnosis of colorectal cancer by colonoscopy increases the probability of survival. However, this is an invasive screening procedure limited by available endoscopy resources and patient compliance. Clearly, a robust non-invasive assay is necessary. In light of the recent advances in proteomics, the investigator proposes to use mass spectrometry-based methods to identify plasma biomarkers for colorectal cancer. To overcome the inherent variability in human studies, the investigator has focused on mouse models of colon cancer. Preliminary data suggest that one is able to identify plasma proteins that act as surrogate markers for cancer in mice with high tumor burdens. The proposed plan extends the preliminary studies to determine if one can: 1) identify mice with minimal tumor burden, 2) discriminate between mice with tubular and villous adenomas, and 3) identify mice with carcinomas. The research will be conducted in the laboratory of Dr. Raju Kucherlapati. The investigator will have full access to the Harvard Partners Center for Genetics and Genomics Proteomics Facility, as well as other facilities throughout the Harvard Longwood Medical area. It is anticipated that the guidance and training received from this program will allow the investigator to achieve his goal: to be an independent researcher in academic gastrointestinal medicine. ? ? Relevance: This proposal will lay the foundation for the identification of biomarkers which may be used for the early detection of colorectal cancer through the analysis of perhaps a single drop of blood. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08DK078033-01
Application #
7143163
Study Section
Subcommittee G - Education (NCI)
Program Officer
Podskalny, Judith M,
Project Start
2006-08-15
Project End
2011-07-31
Budget Start
2006-08-15
Budget End
2007-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$134,325
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Roper, Jatin; Sinnamon, Mark J; Coffee, Erin M et al. (2014) Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett 347:204-11
Li, Xingnan; Nadauld, Lincoln; Ootani, Akifumi et al. (2014) Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med 20:769-77
Martin, Eric S; Belmont, Peter J; Sinnamon, Mark J et al. (2013) Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res 19:2929-40
Coffee, Erin M; Faber, Anthony C; Roper, Jatin et al. (2013) Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 19:2688-98
Roper, Jatin; Richardson, Michael P; Wang, Wei Vivian et al. (2011) The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 6:e25132
Hung, Kenneth E; Maricevich, Marco A; Richard, Larissa Georgeon et al. (2010) Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 107:1565-70
Hung, Kenneth E; Yu, Kenneth H (2010) Proteomic approaches to cancer biomarkers. Gastroenterology 138:46-51.e1
Hung, Kenneth E; Faca, Vitor; Song, Kenneth et al. (2009) Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila) 2:224-33
Forrester, Sara; Hung, Kenneth E; Kuick, Rork et al. (2007) Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer. Mol Oncol 1:216-25